Table 1.
Baseline characteristics of patients with non‐small cell lung cancer with malignant pleural effusion
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Age | 57 | 54 | 67 | 54 |
| Sex | F | M | M | F |
| Morphology | Adenocarcinoma | Adenocarcinoma | Adenocarcinoma | Adenocarcinoma |
| ECOG status | 2 | 2 | 2 | 2 |
| BSA (m2) | 1.83 | 1.88 | 1.59 | 1.91 |
| Smoking history | Never smoker | Former smoker | Never smoker | Never smoker |
| Smoking amount (Pack*years) | 9 | |||
| Discontinuation period (years) | 17 | |||
| Pain scale (VAS) | 3 | 1 | 3 | 4 |
| mMRC grade | 2 | 3 | 2 | 2 |
| The previous treatment before MPE† | Second line | First line | First line | First line |
| EGFR mutation | + | + | − | − |
| Amounts of drained pleural effusion before chest tube insertion (mL) | 1300 | 1500 | 1500 | 720 |
| Pleural fluid analysis | ||||
| pH | 7.2 | 7.8 | 7.6 | 7.8 |
| RBC (/μL) | 48 640 | 98 750 | 900 | 5000 |
| WBC (/μL) | 1000 | 1100 | 2200 | 960 |
| Neutrophils (%) | 3 | 4 | 0 | 1 |
| Lymphocytes (%) | 15 | 54 | 61 | 93 |
| Histiocytes (%) | 51 | 6 | 7 | 4 |
| Eosinophils (%) | 18 | 7 | 0 | 0 |
| Malignant cells (%) | 8 | 28 | 27 | 0 |
| Protein (g/dL) | 5.5 | 5.4 | 4.9 | 5.2 |
| Albumin (g/dL) | 3.1 | 2.7 | 3 | 2.8 |
| Glucose (mg/dL) | 110 | 77 | 83 | 118 |
| LD (U/L) | 180 | 319 | 231 | 282 |
| ADA (IU/L) | 27.2 | 23.5 | 15.5 | 18.1 |
†
Patient 1: Gefitinib > Pemetrexed; Patient 2: Gefitinib; Patient 3: Pemetrexed/Cisplatin; Patient 4: Pemetrexed/Cisplatin.
MPE, malignant pleural effusion.